256 related articles for article (PubMed ID: 25589495)
1. Syngeneic Murine Ovarian Cancer Model Reveals That Ascites Enriches for Ovarian Cancer Stem-Like Cells Expressing Membrane GRP78.
Mo L; Bachelder RE; Kennedy M; Chen PH; Chi JT; Berchuck A; Cianciolo G; Pizzo SV
Mol Cancer Ther; 2015 Mar; 14(3):747-56. PubMed ID: 25589495
[TBL] [Abstract][Full Text] [Related]
2. Modification of the Tumor Microenvironment in KRAS or c-MYC-Induced Ovarian Cancer-Associated Peritonitis.
Yoshida M; Taguchi A; Kawana K; Adachi K; Kawata A; Ogishima J; Nakamura H; Fujimoto A; Sato M; Inoue T; Nishida H; Furuya H; Tomio K; Arimoto T; Koga K; Wada-Hiraike O; Oda K; Nagamatsu T; Kiyono T; Osuga Y; Fujii T
PLoS One; 2016; 11(8):e0160330. PubMed ID: 27483433
[TBL] [Abstract][Full Text] [Related]
3. Elimination of head and neck cancer initiating cells through targeting glucose regulated protein78 signaling.
Wu MJ; Jan CI; Tsay YG; Yu YH; Huang CY; Lin SC; Liu CJ; Chen YS; Lo JF; Yu CC
Mol Cancer; 2010 Oct; 9():283. PubMed ID: 20979610
[TBL] [Abstract][Full Text] [Related]
4. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
[TBL] [Abstract][Full Text] [Related]
5. Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer.
Wilson AJ; Saskowski J; Barham W; Khabele D; Yull F
Mol Cancer; 2015 Nov; 14():192. PubMed ID: 26552746
[TBL] [Abstract][Full Text] [Related]
6. [Effects of ascites derived exosomes on the stemness and invasion ability of ovarian cancer stem-like cell].
Chen SP; Xia YF; Jiang HH; Sun WY; Lou YH
Zhonghua Fu Chan Ke Za Zhi; 2021 May; 56(5):349-357. PubMed ID: 34034422
[No Abstract] [Full Text] [Related]
7. GRP78 secreted by tumor cells stimulates differentiation of bone marrow mesenchymal stem cells to cancer-associated fibroblasts.
Peng Y; Li Z; Li Z
Biochem Biophys Res Commun; 2013 Nov; 440(4):558-63. PubMed ID: 24113381
[TBL] [Abstract][Full Text] [Related]
8. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
K Au K; Peterson N; Truesdell P; Reid-Schachter G; Khalaj K; Ren R; Francis JA; Graham CH; Craig AW; Koti M
Gynecol Oncol; 2017 Jun; 145(3):436-445. PubMed ID: 28318643
[TBL] [Abstract][Full Text] [Related]
9. PPARγ activation modulates the balance of peritoneal macrophage populations to suppress ovarian tumor growth and tumor-induced immunosuppression.
Prat M; Coulson K; Blot C; Jacquemin G; Romano M; Renoud ML; AlaEddine M; Le Naour A; Authier H; Rahabi MC; Benmoussa K; Salon M; Parny M; Delord JP; Ferron G; Lefèvre L; Couderc B; Coste A
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586764
[TBL] [Abstract][Full Text] [Related]
10. Loss of Krüppel-like factor 9 facilitates stemness in ovarian cancer ascites-derived multicellular spheroids via Notch1/slug signaling.
Wang K; Liu S; Dou Z; Zhang S; Yang X
Cancer Sci; 2021 Oct; 112(10):4220-4233. PubMed ID: 34363722
[TBL] [Abstract][Full Text] [Related]
11. Characterization and evaluation of pre-clinical suitability of a syngeneic orthotopic mouse ovarian cancer model.
Cho S; Sun Y; Soisson AP; Dodson MK; Peterson CM; Jarboe EA; Kennedy AM; Janát-Amsbury MM
Anticancer Res; 2013 Apr; 33(4):1317-24. PubMed ID: 23564768
[TBL] [Abstract][Full Text] [Related]
12. Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer.
Wilson AJ; Saskowski J; Barham W; Yull F; Khabele D
J Ovarian Res; 2015 Jul; 8():46. PubMed ID: 26215403
[TBL] [Abstract][Full Text] [Related]
13. Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma.
Zhao Y; Cao J; Melamed A; Worley M; Gockley A; Jones D; Nia HT; Zhang Y; Stylianopoulos T; Kumar AS; Mpekris F; Datta M; Sun Y; Wu L; Gao X; Yeku O; Del Carmen MG; Spriggs DR; Jain RK; Xu L
Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2210-2219. PubMed ID: 30659155
[TBL] [Abstract][Full Text] [Related]
14. Role of M2-like macrophages in the progression of ovarian cancer.
Baek SH; Lee HW; Gangadaran P; Oh JM; Zhu L; Rajendran RL; Lee J; Ahn BC
Exp Cell Res; 2020 Oct; 395(2):112211. PubMed ID: 32755554
[TBL] [Abstract][Full Text] [Related]
15. Ascites Increases Expression/Function of Multidrug Resistance Proteins in Ovarian Cancer Cells.
Mo L; Pospichalova V; Huang Z; Murphy SK; Payne S; Wang F; Kennedy M; Cianciolo GJ; Bryja V; Pizzo SV; Bachelder RE
PLoS One; 2015; 10(7):e0131579. PubMed ID: 26148191
[TBL] [Abstract][Full Text] [Related]
16. Cell surface GRP78 promotes stemness in normal and neoplastic cells.
Conner C; Lager TW; Guldner IH; Wu MZ; Hishida Y; Hishida T; Ruiz S; Yamasaki AE; Gilson RC; Belmonte JCI; Gray PC; Kelber JA; Zhang S; Panopoulos AD
Sci Rep; 2020 Feb; 10(1):3474. PubMed ID: 32103065
[TBL] [Abstract][Full Text] [Related]
17. Autocrine interleukin-23 promotes self-renewal of CD133+ ovarian cancer stem-like cells.
Wang D; Xiang T; Zhao Z; Lin K; Yin P; Jiang L; Liang Z; Zhu B
Oncotarget; 2016 Nov; 7(46):76006-76020. PubMed ID: 27738346
[TBL] [Abstract][Full Text] [Related]
18. Notch3 signaling promotes tumor cell adhesion and progression in a murine epithelial ovarian cancer model.
Price JC; Azizi E; Naiche LA; Parvani JG; Shukla P; Kim S; Slack-Davis JK; Pe'er D; Kitajewski JK
PLoS One; 2020; 15(6):e0233962. PubMed ID: 32525899
[TBL] [Abstract][Full Text] [Related]
19. Ovarian Cancer Stem Cells with High ROR1 Expression Serve as a New Prophylactic Vaccine for Ovarian Cancer.
Wu D; Yu X; Wang J; Hui X; Zhang Y; Cai Y; Ren M; Guo M; Zhao F; Dou J
J Immunol Res; 2019; 2019():9394615. PubMed ID: 31008116
[TBL] [Abstract][Full Text] [Related]
20. Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer.
Glass EB; Hoover AA; Bullock KK; Madden MZ; Reinfeld BI; Harris W; Parker D; Hufnagel DH; Crispens MA; Khabele D; Rathmell WK; Rathmell JC; Wilson AJ; Giorgio TD; Yull FE
BMC Cancer; 2022 May; 22(1):497. PubMed ID: 35513776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
